Latest News and Press Releases

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...

- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...

- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR - AUTO1/22 may reduce CD19 negative escape in children with B-ALL, and may have broader applications in...

Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...

obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...